Why Some Employers May Spend More on GLP-1s Than They Spend on Dental Benefits

For decades, dental benefits have been viewed as one of the most stable and predictable components of an employer's benefit package. That reality is beginning to change — not because dental costs are increasing dramatically, but because GLP-1 spending is growing at a pace few employers anticipated.

Consider a hypothetical employer with 10,000 covered employees. If only 5 percent of the population utilizes GLP-1 medications and the annual cost averages $8,000 to $12,000 per participant, annual spending can quickly reach $4 million to $6 million. If utilization rises to 10 percent, the annual expenditure may approach or exceed $10 million. Many employers spend less on dental benefits than they would spend covering a relatively small percentage of employees with GLP-1 medications.

The Cost Debate Often Misses the Bigger Picture

Much of the discussion surrounding GLP-1 medications focuses on whether employers should cover them. The larger issue is why so many employees qualify for these treatments in the first place. The growth in GLP-1 utilization reflects a broader increase in obesity, diabetes, metabolic syndrome, cardiovascular risk, and related chronic conditions. The medications did not create these problems. They are a response to them.

The long-term challenge is not simply managing medication costs. It is managing population health. Organizations that understand those trends early will be better positioned to make informed decisions about benefits strategy, workforce health, and long-term cost management.